Zimmer Biomet (NYSE:ZBH) SVP Sells $156,225.00 in Stock

by · The Cerbat Gem

Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Free Report) SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares in the company, valued at approximately $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Zimmer Biomet Stock Performance

ZBH stock opened at $104.22 on Friday. The business’s 50-day moving average price is $99.27 and its two-hundred day moving average price is $99.62. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The firm has a market cap of $20.65 billion, a PE ratio of 25.36, a P/E/G ratio of 2.35 and a beta of 0.68. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last posted its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. The firm had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Analysts Set New Price Targets

Several research firms have issued reports on ZBH. UBS Group lifted their price target on Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a research note on Friday, August 8th. Raymond James Financial lifted their price target on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Royal Bank Of Canada lifted their price target on Zimmer Biomet from $112.00 to $115.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Roth Capital reissued a “buy” rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Finally, Evercore ISI dropped their target price on Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating on the stock in a report on Tuesday, July 8th. Nine equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $111.00.

Read Our Latest Report on Zimmer Biomet

Institutional Trading of Zimmer Biomet

Institutional investors and hedge funds have recently bought and sold shares of the business. OneDigital Investment Advisors LLC bought a new stake in Zimmer Biomet in the first quarter valued at approximately $269,000. Keybank National Association OH raised its stake in Zimmer Biomet by 61.2% in the first quarter. Keybank National Association OH now owns 14,315 shares of the medical equipment provider’s stock valued at $1,620,000 after buying an additional 5,434 shares during the period. Envestnet Asset Management Inc. raised its stake in Zimmer Biomet by 26.4% in the first quarter. Envestnet Asset Management Inc. now owns 316,308 shares of the medical equipment provider’s stock valued at $35,800,000 after buying an additional 66,114 shares during the period. Kingswood Wealth Advisors LLC raised its stake in Zimmer Biomet by 20.0% in the first quarter. Kingswood Wealth Advisors LLC now owns 2,605 shares of the medical equipment provider’s stock valued at $295,000 after buying an additional 435 shares during the period. Finally, QRG Capital Management Inc. raised its stake in Zimmer Biomet by 13.9% in the first quarter. QRG Capital Management Inc. now owns 6,775 shares of the medical equipment provider’s stock valued at $767,000 after buying an additional 827 shares during the period. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

(Get Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Featured Stories